Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.22)
# 4,379
Out of 5,182 analysts
9
Total ratings
25%
Success rate
-28.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Outperform | $45 → $32 | $13.61 | +135.12% | 2 | Apr 2, 2026 | |
| INCY Incyte | Maintains: In-Line | $73 → $110 | $97.74 | +12.54% | 2 | Mar 5, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $38.15 | +25.82% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $10.88 | +175.74% | 2 | Mar 22, 2023 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $0.74 | +3,008.11% | 1 | May 25, 2021 |
Viridian Therapeutics
Apr 2, 2026
Maintains: Outperform
Price Target: $45 → $32
Current: $13.61
Upside: +135.12%
Incyte
Mar 5, 2026
Maintains: In-Line
Price Target: $73 → $110
Current: $97.74
Upside: +12.54%
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $38.15
Upside: +25.82%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $10.88
Upside: +175.74%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $0.74
Upside: +3,008.11%